Navigation Links
Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
Date:12/6/2007

ssure that the necessary audio applications are downloaded and installed. These programs can be obtained at no charge to the user.

A replay of the call will be available two hours after the completion of the call at (888) 286-8010 in the U.S., ((617) 801-6888 for international callers), pass code 74113063. The replay will be available through Monday, December 24, 2007.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with hematopoietic cell transplantion in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding t
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- The ... recombinant proteins, is placing renewed emphasis on alternate ... rise as a number of factors are converging ... pharmaceutical makers and their delivery device partners . ... refractory conditions, the growing trend toward self-administration for ...
(Date:5/17/2013)... -- Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) a ... patent-pending technologies poised to redefine how consumers receive energy, medicines, ... business update teleconference and webcast for shareholders and the investment ... PM ET. Fuse Science, Inc. CEO, ... will be joined by Rubin Hanan , ...
(Date:5/17/2013)... 17, 2013  PENTAX Medical, a healthcare industry ... global leader in ultrasound imaging, recently announced renewed ... enable further innovation in the development of Endoscopic ... systems and PENTAX Medical endoscopic portfolio have formed ... EUS systems. This agreement will continue to grow ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3
... of Hypertension,s Twenty-Third ... Annual Scientific Meeting - A cumulative forty-five percent ... of BENICAR(R) (olmesartan medoxomil), and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) achieved ... normotension (< 120/80 mm Hg) (placebo:1.4%)., - Eight out of 10 (cumulative ...
... Florida and Scripps Research in La ... ... and LA JOLLA, Calif., May 14 /PRNewswire-,FirstCall/ -- Poniard Pharmaceuticals, Inc. ... Scripps Research,Institute, a non-profit biomedical research organization, today announced,that an agreement ...
Cached Medicine Technology:New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 4
(Date:5/19/2013)... Today, Zane Benefits, Inc. published ... insurance . Zane Benefits, which provides comprehensive and ... is the leader in health care reform, ... . , According to Zane Benefits’ website, many ... the value of small business health insurance for ...
(Date:5/19/2013)... Corpus Christi, TX (PRWEB) May 19, 2013 ... home security systems companies. Homeowners who are considering ... options and services of the nation's leading security system ... security systems reviews the best DIY home security ... results. Every year 6Webs.com reviews dozens of home security ...
(Date:5/19/2013)... Fat Burning Furnace developed by Rob ... people with fat burning diet plans, training ... Burning Furnace package, people will receive the Fat Burning ... quickly. The Fat Burning Furnace manual includes fat loss ... muscle mass. In addition, this book covers step-by-step instructions, ...
(Date:5/19/2013)... Farming methods have changed many times ... 10,000 years ago. Most recently, the Green Revolution has ... genetically engineered seeds and by applying chemical fertilizers and ... these techniques due to the adverse environmental and health ... surge in interest in organic, sustainable farming practices and ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Vegas Hotel ... is proud to announce the launch it's all new ... the MGM Grand on 5/19/2013. Consumers traveling to Las ... special pricing available on VegasHotelEscapes.com's website. Travelers will be ... beat any competitors price. , Vegas Hotel Escapes specializes ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Top Rated DIY Home Security System Companies Published by 6Webs.com 2Health News:Fat Burning Diet | How “Fat Burning Furnace” Helps People Lose Their Weight Naturally And Fast – V-kool 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3
... were women who also received training to manage the ... may seem best at preventing illness rather than treating ... activity could make an immediate difference for people with ... chronic pain syndrome who exercised moderately for four months ...
... University of Virginia clinical psychologists has found that teens who ... to exhibit delinquent behavior in early adulthood than their peers ... study also suggests that early sex may play a role ... adulthood., The finding is published in the current online edition ...
... Terms, quarterly report analyzes the information, needs that drove ... ... third quarter, NEW YORK, Nov. 12 ... ongoing series of quarterly reports intended to shed light on,the most ...
... Company Brings Global U.N. Environmental Initiative to ... its,commitment to sustainability and social responsibility, today ... up their sleeves, grabbed their spades and ... company announced that it has joined the ...
... on Striking Nurses, BECKLEY, W.Va., Nov. 12 ... Health Care (ARH), represented by,the Kentucky and West ... to call public attention to the underhanded and,violent ... their strike,which began Oct. 1. ARH has escalated ...
... eDiets.com,Inc. (Nasdaq: DIET ), leveraging the power ... consumers and businesses, today announced that it,has rescheduled ... report results for its third quarter ended September ... Wednesday, November 14, 2007 and,will host a conference ...
Cached Medicine News:Health News:Exercise Eases Fibromyalgia Symptoms: Study 2Health News:Exercise Eases Fibromyalgia Symptoms: Study 3Health News:Early teen sex may not be a path to delinquency, study shows 2Health News:SearchMedica.com Reveals Top Searches Among Medical Professionals 2Health News:SearchMedica.com Reveals Top Searches Among Medical Professionals 3Health News:Bayer Plants Trees With Chartiers Valley Intermediate School Students, Provides Free Environmental Education Materials 2Health News:Bayer Plants Trees With Chartiers Valley Intermediate School Students, Provides Free Environmental Education Materials 3Health News:Bayer Plants Trees With Chartiers Valley Intermediate School Students, Provides Free Environmental Education Materials 4Health News:Nurses Protest Violent Tactics Against Picketers 2Health News:eDiets.com(R) Updates Timing of Third Quarter 2007 Earnings Conference Call 2
Straight shafts with heavy Elschnig teeth. Flat serrated handle with slide style lock and polished finished....
Straight shafts with fine Pierse type tips. Flat smooth handle with dull finish....
Straight shafts with 1 x 2 Elsching style teeth. Wide serrated handle with polished finish....
Straight crisscross serrated tips. Flat handle with holes and polished finish....
Medicine Products: